{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:35:48Z","timestamp":1790994948817,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CB06\/05\/0089"],"award-info":[{"award-number":["CB06\/05\/0089"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021\\u2013128906OB-I00"],"award-info":[{"award-number":["PID2021\\u2013128906OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RTI-2018\\u2013098885-B-I00"],"award-info":[{"award-number":["RTI-2018\\u2013098885-B-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019887","name":"GW Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015496","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015496","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118288","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T21:10:36Z","timestamp":1750972236000},"page":"118288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis"],"prefix":"10.1016","volume":"189","author":[{"given":"Laura","family":"Garc\u00eda-Toscano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rodr\u00edguez-Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Furiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"de Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118288_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-3940(01)02065-1","article-title":"Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity","volume":"309","author":"Abood","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2025.118288_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnins.2020.00042","article-title":"The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia","volume":"14","author":"Abramzon","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2025.118288_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrneurol.2013.203","article-title":"The epidemiology of ALS: a conspiracy of genes, environment and time","volume":"9","author":"Al-Chalabi","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.biopha.2025.118288_bib4","first-page":"165","article-title":"Sodium phenylbutyrate and taurursodiol: a new therapeutic option for the treatment of amyotrophic lateral sclerosis","volume":"58","author":"Alqallaf","year":"2024","journal-title":"Ann. Pharm."},{"key":"10.1016\/j.biopha.2025.118288_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","article-title":"Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets","volume":"64","author":"Alvarez","year":"2008","journal-title":"Pedia Res."},{"key":"10.1016\/j.biopha.2025.118288_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcp.2018.08.016","article-title":"Cannabinoid pharmacology\/therapeutics in chronic degenerative disorders affecting the central nervous system","volume":"157","author":"Aymerich","year":"2018","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2025.118288_bib7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1755-5949.2009.00116.x","article-title":"A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?","volume":"17","author":"Bellingham","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.biopha.2025.118288_bib8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1096\/fj.05-4743fje","article-title":"Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice","volume":"20","author":"Bilsland","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2025.118288_bib9","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2174\/138161208785740081","article-title":"The endocannabinoid system in amyotrophic lateral sclerosis","volume":"14","author":"Bilsland","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2025.118288_bib10","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/bph.15148","article-title":"Targeting TDP-43 proteinopathy with drugs and drug-like small molecules","volume":"178","author":"Buratti","year":"2021","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118288_bib11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3389\/fgene.2018.00712","article-title":"RNA dysregulation in amyotrophic lateral sclerosis","volume":"9","author":"Butti","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.biopha.2025.118288_bib12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/biom12081084","article-title":"Minor phytocannabinoids: a misleading name but a promising opportunity for biomedical research","volume":"12","author":"Caprioglio","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118288_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/1049909110369531","article-title":"Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials","volume":"27","author":"Carter","year":"2010","journal-title":"Am. J. Hosp. Palliat. Care"},{"key":"10.1016\/j.biopha.2025.118288_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuropharm.2016.12.017","article-title":"Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke","volume":"116","author":"Cepri\u00e1n","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118288_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/jnnp-2020-322983","article-title":"TDP-43 proteinopathies: a new wave of neurodegenerative diseases","volume":"92","author":"de Boer","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118288_bib16","series-title":"In Cannabinoids in Neurologic and Mental Disease (Fattore L, Ed.)","first-page":"99","article-title":"Endocannabinoids and amyotrophic lateral sclerosis","author":"de Lago","year":"2015"},{"key":"10.1016\/j.biopha.2025.118288_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/21678421.2018.1425454","article-title":"Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients","volume":"19","author":"Espejo-Porras","year":"2018","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"10.1016\/j.biopha.2025.118288_bib18","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/bph.14216","article-title":"Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis","volume":"176","author":"Espejo-Porras","year":"2019","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118288_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11481-015-9602-4","article-title":"Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders","volume":"10","author":"Espejo-Porras","year":"2015","journal-title":"J. Neuroimmune Pharm."},{"key":"10.1016\/j.biopha.2025.118288_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s13311-015-0381-7","article-title":"Cannabinoids in neurodegenerative disorders and stroke\/brain trauma: from preclinical models to clinical applications","volume":"12","author":"Fern\u00e1ndez-Ruiz","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biopha.2025.118288_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","article-title":"Cannabinoid CB2 receptor: a new target for controlling neural cell survival?","volume":"28","author":"Fern\u00e1ndez-Ruiz","year":"2007","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118288_bib22","first-page":"551","article-title":"Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis","volume":"10","author":"Fern\u00e1ndez-Trapero","year":"2017","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.biopha.2025.118288_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrneurol.2011.152","article-title":"Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis","volume":"7","author":"Ferraiuolo","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.biopha.2025.118288_bib24","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.3390\/molecules25112638","article-title":"-Cannabidiolic acid, a still overlooked bioactive compound: an introductory review and preliminary research","volume":"25","author":"Formato","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118288_bib25","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00702-020-02213-y","article-title":"Development of neurodegeneration in amyotrophic lateral sclerosis: from up or down?","volume":"127","author":"Geser","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.biopha.2025.118288_bib26","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026757","article-title":"The genetics of C9orf72 expansions","volume":"8","author":"Gijselinck","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2025.118288_bib27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","article-title":"Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease","volume":"64","author":"G\u00f3mez-G\u00e1lvez","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118288_bib28","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.tplants.2020.05.005","article-title":"Phytocannabinoids: origins and biosynthesis","volume":"25","author":"G\u00fclck","year":"2020","journal-title":"Trends Plant Sci."},{"key":"10.1016\/j.biopha.2025.118288_bib29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/14728214.2011.604312","article-title":"Emerging drugs for amyotrophic lateral sclerosis","volume":"16","author":"Habib","year":"2011","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.biopha.2025.118288_bib30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","article-title":"Clinical diagnosis and management of amyotrophic lateral sclerosis","volume":"7","author":"Hardiman","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.biopha.2025.118288_bib31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/21678421.2017.1407796","article-title":"Riluzole does not improve lifespan or motor function in three ALS mouse models","volume":"19","author":"Hogg","year":"2018","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"10.1016\/j.biopha.2025.118288_bib32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s004010050535","article-title":"Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu\/Zn superoxide dismutase gene: pathological and immunocytochemical changes","volume":"92","author":"Ince","year":"1996","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.biopha.2025.118288_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jmedgenet-2016-104271","article-title":"Genetics insight into the amyotrophic lateral sclerosis\/frontotemporal dementia spectrum","volume":"54","author":"Ji","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.biopha.2025.118288_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gene.2015.11.049","article-title":"Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis","volume":"577","author":"Kaur","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.biopha.2025.118288_bib35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejphar.2006.05.025","article-title":"AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis","volume":"542","author":"Kim","year":"2006","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118288_bib36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.cell.2009.03.006","article-title":"Rethinking ALS: the FUS about TDP-43","volume":"136","author":"Lagier-Tourenne","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118288_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/jpm10030101","article-title":"Molecular and cellular mechanisms affected in ALS","volume":"10","author":"Le Gall","year":"2020","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.biopha.2025.118288_bib38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/cns.12262","article-title":"Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex\u00ae-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis","volume":"20","author":"Moreno-Martet","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.biopha.2025.118288_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1538\/expanim.14-0077","article-title":"Comparative study of behavioural tests in the SOD1G93A mouse model of amyotrophic lateral sclerosis","volume":"64","author":"Oliv\u00e1n","year":"2015","journal-title":"Exp. Anim."},{"key":"10.1016\/j.biopha.2025.118288_bib40","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2025.118288_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neuropharm.2017.03.037","article-title":"Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS","volume":"124","author":"Pasquarelli","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118288_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14660820310016813","article-title":"Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid","volume":"5","author":"Raman","year":"2004","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron. Disord."},{"key":"10.1016\/j.biopha.2025.118288_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nn.3584","article-title":"State of play in amyotrophic lateral sclerosis genetics","volume":"17","author":"Renton","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.biopha.2025.118288_bib44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2025.118288_bib45","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1073\/pnas.92.3.689","article-title":"Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis","volume":"92","author":"Ripps","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118288_bib46","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/bph.15386","article-title":"Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis","volume":"178","author":"Rodr\u00edguez-Cueto","year":"2021","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2025.118288_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.12972","article-title":"Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis","volume":"31","author":"Rodr\u00edguez-Cueto","year":"2021","journal-title":"Brain Pathol."},{"key":"10.1016\/j.biopha.2025.118288_bib48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bcp.2018.07.049","article-title":"Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis","volume":"157","author":"Rodr\u00edguez-Cueto","year":"2018","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2025.118288_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118288_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.expneurol.2010.03.030","article-title":"The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis","volume":"224","author":"Rossi","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2025.118288_bib51","first-page":"7","article-title":"Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis","volume":"68","author":"Rothstein","year":"1995","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.biopha.2025.118288_bib52","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.cell.2017.10.011","article-title":"Edaravone: a new drug approved for ALS","volume":"171","author":"Rothstein","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118288_bib53","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2025.118288_bib54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1471-4159.2006.04346.x","article-title":"The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset","volume":"101","author":"Shoemaker","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2025.118288_bib55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21678421.2017.1353101","article-title":"Edaravone and its clinical development for amyotrophic lateral sclerosis","volume":"18","author":"Takei","year":"2017","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"10.1016\/j.biopha.2025.118288_bib56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","article-title":"The epidemiology of amyotrophic lateral sclerosis","volume":"138","author":"Talbott","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.biopha.2025.118288_bib57","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.brainres.2012.04.031","article-title":"Rodent models of TDP-43: recent advances","volume":"1462","author":"Tsao","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2025.118288_bib58","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11910-009-0030-9","article-title":"Recent advances in the genetics of amyotrophic lateral sclerosis","volume":"9","author":"Valdmanis","year":"2009","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.biopha.2025.118288_bib59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1242\/dmm.029058","article-title":"Modelling amyotrophic lateral sclerosis: progress and possibilities","volume":"10","author":"Van Damme","year":"2017","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.biopha.2025.118288_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777804","article-title":"Minor cannabinoids: biosynthesis, molecular pharmacology and potential therapeutic uses","volume":"12","author":"Walsh","year":"2021","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2025.118288_bib61","doi-asserted-by":"crossref","first-page":"18809","DOI":"10.1073\/pnas.0908767106","article-title":"TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration","volume":"106","author":"Wegorzewska","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118288_bib62","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/14660820510030149","article-title":"Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival","volume":"6","author":"Weydt","year":"2005","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"10.1016\/j.biopha.2025.118288_bib63","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/j.1471-4159.2004.02544.x","article-title":"Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice","volume":"89","author":"Witting","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2025.118288_bib64","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1111\/ejn.15422","article-title":"Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis","volume":"54","author":"Wright","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118288_bib65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnmol.2020.00078","article-title":"Dysregulation of RNA-binding proteins in amyotrophic lateral sclerosis","volume":"13","author":"Xue","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2025.118288_bib66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC Neurol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:53:52Z","timestamp":1754654032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":66,"alternative-id":["S0753332225004822"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118288","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118288"}}